Zacks Research Weighs in on OPKO Health FY2027 Earnings

OPKO Health, Inc. (NASDAQ:OPK - Free Report) - Zacks Research issued their FY2027 earnings estimates for shares of OPKO Health in a research report issued to clients and investors on Thursday, March 20th. Zacks Research analyst R. Department expects that the biotechnology company will post earnings of ($0.09) per share for the year. The consensus estimate for OPKO Health's current full-year earnings is ($0.25) per share.

OPKO Health (NASDAQ:OPK - Get Free Report) last posted its earnings results on Thursday, February 27th. The biotechnology company reported $0.01 EPS for the quarter, beating analysts' consensus estimates of ($0.08) by $0.09. The company had revenue of $183.60 million for the quarter, compared to the consensus estimate of $155.42 million. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%.

OPK has been the subject of a number of other research reports. HC Wainwright reaffirmed a "buy" rating and set a $3.00 price objective on shares of OPKO Health in a research report on Wednesday, March 19th. Barrington Research restated an "outperform" rating and set a $2.25 price target on shares of OPKO Health in a research report on Wednesday, March 12th. Finally, StockNews.com upgraded OPKO Health from a "sell" rating to a "hold" rating in a report on Monday, March 3rd.

Remove Ads

OPKO Health Trading Down 1.7 %

NASDAQ OPK traded down $0.03 during trading hours on Monday, reaching $1.74. The company had a trading volume of 2,164,174 shares, compared to its average volume of 4,841,456. OPKO Health has a 1-year low of $1.12 and a 1-year high of $2.04. The stock has a market capitalization of $1.17 billion, a P/E ratio of -9.16 and a beta of 1.70. The stock has a 50-day moving average of $1.67 and a 200 day moving average of $1.58. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30.

Insiders Place Their Bets

In related news, CEO Phillip Md Et Al Frost acquired 200,000 shares of the stock in a transaction dated Monday, March 17th. The stock was acquired at an average cost of $1.74 per share, with a total value of $348,000.00. Following the completion of the transaction, the chief executive officer now owns 213,501,448 shares in the company, valued at $371,492,519.52. This represents a 0.09 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders have acquired a total of 964,971 shares of company stock worth $1,493,692 in the last ninety days. 47.26% of the stock is owned by corporate insiders.

Institutional Trading of OPKO Health

Several hedge funds have recently added to or reduced their stakes in OPK. FMR LLC raised its stake in OPKO Health by 103.6% in the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company's stock valued at $32,000 after buying an additional 11,089 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its stake in OPKO Health by 75.3% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 28,908 shares of the biotechnology company's stock worth $42,000 after acquiring an additional 12,417 shares in the last quarter. Orion Portfolio Solutions LLC acquired a new position in OPKO Health in the third quarter valued at $45,000. Cibc World Markets Corp acquired a new position in OPKO Health in the fourth quarter valued at $45,000. Finally, Zacks Investment Management acquired a new stake in shares of OPKO Health during the fourth quarter worth about $49,000. Institutional investors and hedge funds own 64.63% of the company's stock.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.